Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beijing Biostar Pharmaceuticals Co's total inventories for the quarter that ended in Dec. 2025 was HK$50.26 Mil. Beijing Biostar Pharmaceuticals Co's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was HK$47.31 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Beijing Biostar Pharmaceuticals Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$1.14.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Beijing Biostar Pharmaceuticals Co's Days Inventory for the
six
months ended in Dec. 2025 was 4,987.96.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Beijing Biostar Pharmaceuticals Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 0.04.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Beijing Biostar Pharmaceuticals Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 2.31.
Beijing Biostar Pharmaceuticals Co (HKSE:02563) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Beijing Biostar Pharmaceuticals Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Beijing Biostar Pharmaceuticals Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Beijing Biostar Pharmaceuticals Co Total Inventories Related Terms
Beijing Biostar Pharmaceuticals Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Biostar Pharmaceuticals Co Total Inventories Chart
Beijing Biostar Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Total Inventories
34.74
29.82
33.55
50.26
Beijing Biostar Pharmaceuticals Co Semi-Annual Data
Beijing Biostar Pharmaceuticals Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of HK$50.26 Mil mean?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a Total Inventories of HK$50.26 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Beijing Biostar Pharmaceuticals Co and its competitors.
Is Beijing Biostar Pharmaceuticals Co's Total Inventories too high?
Beijing Biostar Pharmaceuticals Co's current Total Inventories is HK$50.26 Mil. Overall, Beijing Biostar Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Biostar Pharmaceuticals Co's Total Inventories compare to VRTX and REGN?
Beijing Biostar Pharmaceuticals Co's Total Inventories of HK$50.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Beijing Biostar Pharmaceuticals Co and its competitors. Beijing Biostar Pharmaceuticals Co's current Total Inventories is HK$50.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Biostar Pharmaceuticals Co stock overvalued right now?
Beijing Biostar Pharmaceuticals Co (HKSE:02563) has a current Total Inventories of HK$50.26 Mil. The current Total Inventories is HK$50.26 Mil. Beijing Biostar Pharmaceuticals Co's overall GF Score™ is 9/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Beijing Biostar Pharmaceuticals Co (HKSE:02563), the current Total Inventories is HK$50.26 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beijing Biostar Pharmaceuticals Co Ltd is a synthetic biology-driven biopharmaceutical company committed to developing drugs in oncology. It has developed three core technology platforms that focus on the R&D of microbial metabolite new drugs. Its Core Product and 16 out of 19 product candidates are based on a single active pharmaceutical ingredient, namely, Utidelone, which was represented in three formulations of its product portfolio. The company's current clinical trials and programs of the Core Product and product candidates cover indications of advanced breast cancer, advanced non-small cell lung cancer, neoadjuvant for breast cancer, gastric cancer, esophageal cancer, breast cancer brain metastasis, lung cancer brain metastasis, glioblastoma, and other solid tumors.
9GF Score
Get the complete analysis for HKSE:02563
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02563 has been successfully added to your 
